FUJIFILM Cellular Dynamics, Inc’s Post

The Continuous Paired Associate Learning Test (CPAL) is a digital, non-verbal, pattern space association learning test with strong validity to human learning networks 🧠. The assessment is highly sensitive to disruptions of human memory systems and is effective across many diseases and disorders. Notable use cases for CPAL include the Australian Imaging, Biomarkers, and Lifestyle (AIBL) study, the PERSPECTIVE sacubitril/valsartan trial, and an ongoing pivotal, phase 3 Alzheimer’s disease trial. More details on CPAL and the many other digitial cognitive assessments on the Cogstate platform can be found here 👉 https://lnkd.in/e53Wt6tC #Cognition #BrainHealthForAll #Neuroscience #ClinicalTrials

🔬 Advancing Pain Research with DRG Cell Recordings Our San Diego platform excels in recording from dorsal root ganglion (DRG) cells, providing essential data for drug development. We specialize in recordings from various tissue sources, including those from larger animals, which are critical for generating data with greater translational relevance. By studying these complex systems, we gain richer insights into pain mechanisms, leading to more accurate predictions of human responses. 🔗 Read more: Discover the full potential of DRG sensory neuron recordings and how they can accelerate your pain drug discovery efforts: https://lnkd.in/eHSkY3bP ✉️ Are you currently studying a compound targeting Pain? Reach out to contact@neuroservices-alliance.com or schedule an introductory meeting with us: https://lnkd.in/eEkM9xDN #Neuroscience #PainResearch #CNS #Electrophysiology #DRG

DRG are the first “integration center” on the pain pathways. This is the first level where pharmacological modulation can take place. We offer all the ways (in vitro and in vivo) to investigate the pharmacological properties of your compound on sensory neurons!

Save the date: January 30th, FCDI scientists share how cutting-edge models are accelerating discovery across cardiac, hepatic, neural, and immune systems with data-driven examples and case studies, leveraging recently developed platforms. Learn more and register here! https://ow.ly/76Wt50Qn7pj #iPSC #drugdiscovery #StemCells #neuroscience #DiseaseModeling #DrugDevelopment #3DCellCuture #Neuroinflammation #drugscreening

Live-cell analysis of 3D models is revolutionizing our understanding of this devastating condition by providing more biologically relevant insights. In addition to better in-vitro models, improved assays and technologies that can capture the data generated by these models are vital to accelerate therapeutic developments for Alzheimer's Disease. Download this white paper to learn how live cell analysis of 2D and 3D models provides a better understanding of the mechanism of AD by addressing the limitations of traditional methods. Read now: https://ow.ly/kqnY50Q8T8b #alzheimers #neuroscience #3dcellmodels #livecellanalysis

A novel engineered assembloid platform may help accelerate therapeutic discovery for Parkinson’s disease (PD). Congratulations to Alp Ozgun, David Lomboni, Fabio Variola, and their team, for the important paper 📝 describing the development of a novel engineered assembloid platform to recapitulate key attributes of PD dysfunction in vitro. Visit our website to learn more and discover how the researchers used Axion’s next-generation Maestro Pro MEA platform to explore the dysfunctional dopaminergic network associated with PD in real time with no labels, dyes, or complicated steps.  🔗 https://bit.ly/3PGneLr #parkinsonsdiseaseresearch #iPSCs #neuroscience

Exciting times are ahead in the world of drug discovery and clinical translation! It's time to take a deep dive into the revolutionary use of human iPSC models in our upcoming, iForum™ Innovation Showcase: Implementing human iPSC models to speed drug discovery and improve clinical translation. Learn from FCDI scientists how these cutting-edge models are accelerating drug discovery across cardiac, hepatic, neural, and immune systems. More importantly, understand how these latest trends are poised to change the game in the healthcare industry. We will share data-driven examples and case studies, leveraging FCDI’s recently developed platforms. Each discussion will be chock full of insights, takeaways, and opportunities for future implementation. Tailor your participation to specific talks or immerse yourself in the entire 2-hour presentation – the choice is yours. Learn more and register here! https://ow.ly/76Wt50Qn7pj #iPSC #drugdiscovery #StemCells #neuroscience #DiseaseModeling #DrugDevelopment #3DCellCuture #Neuroinflammation

Exciting times are ahead in the world of drug discovery and clinical translation! It's time to take a deep dive into the revolutionary use of human iPSC models in our upcoming, iForum™ Innovation Showcase: Implementing human iPSC models to speed drug discovery and improve clinical translation. Learn from FCDI scientists how these cutting-edge models are accelerating drug discovery across cardiac, hepatic, neural, and immune systems. More importantly, understand how these latest trends are poised to change the game in the healthcare industry. We will share data-driven examples and case studies, leveraging FCDI’s recently developed platforms. Each discussion will be chock full of insights, takeaways, and opportunities for future implementation. Tailor your participation to specific talks or immerse yourself in the entire 2-hour presentation – the choice is yours. Learn more and register here! https://ow.ly/76Wt50Qn7pj #iPSC #drugdiscovery #StemCells #neuroscience #DiseaseModeling #DrugDevelopment #3DCellCuture #Neuroinflammation

Join FCDI on January 30th to learn more about how human iPSC-derived cells can acclerate your discovery research!

Vigil Neuroscience IGNITE trial update for iluzanebart in ALSP shows agility in the competitive neuroscience landscape. By adapting to FDA guidance and focusing on 12-month data, they're balancing regulatory compliance with potential accelerated approval. This move in the rare disease space could differentiate Vigil from competitors focused on more common neurodegenerative conditions. With results expected in early 2025, Vigil is setting clear expectations for stakeholders. Their strategy highlights the importance of regulatory flexibility and robust data in the fast-paced neuroscience biotech sector. Success here could attract more attention to rare neurodegenerative diseases, potentially shifting industry focus. #Neuroscience #BiotechInnovation #RareDiseases #ClinicalTrials